Background: Thousands of SNPs associated with risk of Alzheimer's disease (AD) in genome-wide
Introduction
Genetic background strongly determines the risk of sporadic Alzheimer's Disease (AD). 1 Apart from the APOE4 polymorphism and 42 other genetic loci, thousands of SNPs associated with risk of AD do not reach genome-wide significance. [2] [3] [4] Polygenic risk scores (PRSs) incorporate the contribution of these variations and relate that to disease risk. 5 PRSs for AD currently reach a prediction accuracy of 84%, albeit that a major proportion can be attributed to APOE status alone. 6 A crucial question is whether AD risk genes functionally link to amyloid-β (Aβ) or TAU pathology or whether they define many parallel pathways that all lead to AD. We expect that at least part of the genes and pathways implicated in genome-wide association studies (GWAS) affect the cellular response of the brain to Aβ or TAU pathology. 7 Such a model integrates parts of the amyloid hypothesis with the complex genetics of AD, which will lead to a more coherent view on the pathogenesis of AD.
Profiling of postmortem brain tissue only provides insights into the advanced stages of AD and cannot delineate cause-consequence relationships, which is required to develop mechanistic models for the pathogenesis of AD. Transgenic mouse models only partially recapitulate AD or frontotemporal dementia (FTD) phenotypes, but they provide detailed functional insights into the initial steps of disease, which is of high relevance for preventative therapeutic interventions. 8 What is lacking until now, however, is the integration of functional information from mouse studies with the GWAS data obtained in human. By doing so, it might be possible to determine whether sub-significant AD risk genes, are involved in the cellular response to Aβ or TAU pathology. This would increase confidence that these genes are truly involved in AD and indicate in which pathways these genes play a functional role.
Here, we perform transcriptional profiling of mouse hippocampus after exposure to Aβ or TAU pathology, at early (4 months of age (4M)) and mature stages of disease (10M). We used APP swe /PS1 L166P (APPtg) and Thy-TAU22 (TAUtg) mice, both expressing the transgene from a Thy1.2 promotor. 9, 10 Despite similar robust cognitive phenotypes, APPtg mice develop severe age-dependent transcriptional deregulation, while TAUtg mice have a milder and over time more stable molecular 4 phenotype. AD risk genes uniquely converge in APPtg mice into a coordinated deregulated multicellular gene network that is strongly enriched in neuroinflammatory functions. Our work provides evidence that a large part of the genetic risk of AD is determining the microglial response to Aβ, and promotes 11 candidate GWAS genes for future AD research.
Results
At 4M of age, APPtg and TAUtg mice are cognitively intact with mild levels of pathology, whereas they display at 10M overlapping profiles of hippocampus-dependent mnemonic deficits and substantial pathology. [9] [10] [11] mRNAseq was performed on the hippocampus of 4M and 10M APPtg and TAUtg mice (TG) and their respective wild-type (WT) littermates, with n=12 per group and n=96 in total, yielding on average 7.7 million reads per sample (see Fig.1A ).
Enrichment of AD risk genes is only found in the transcriptomic response of APPtg mice
A 2x2 linear model (Fig.1B ) was employed to investigate the effects of genotype, age, and age*genotype interaction. The age comparison identifies transcripts changed between 4M and 10M old mice (Fig.2A ). The genotype comparison shows mRNAs different between WT and TG mice (Fig.2B ).
The age*genotype interaction, finally, assesses which transcripts change with aging uniquely in the TG mice (Fig.2C) . The study thus reflects the transcriptional changes manifesting in the mice at two critical time points: initially when the first signs of Aβ and TAU pathology occur and later on, when the biochemical alterations are manifest and accompanied by cognitive deficits.
We wondered whether GWAS-based AD risk genes would be equally responsive to Aβ or TAU pathology. We included both established AD risk genes, i.e. genes with p-value<5x10e-8 in various GWAS studies, as well as subthreshold AD risk genes as these contribute significantly to AD risk predictions through polygenic inheritance. 6 We examined multiple sets of such genes taken from Marioni et al., which combines UK Biobank AD-by-proxy data with the IGAP database. 2 By using 5 arbitrary p-value cut-offs with decreasing significance for AD association, genes sets of increasing size were created (see Fig.1C and Supplementary Table 2) . PRS studies have demonstrated that GWAS SNPs up to a cutoff of p<0.5 still improve the predictive power of risk score. We decided to limit our study to a cutoff of p<0.05, yielding an already large set of 1799 genes. The enrichment of these AD risk gene sets in the different transcriptional responses of the mice was assessed using gene set enrichment analysis (GSEA). The data (Fig.1C) demonstrate that independently of the set size, ranging from 92
genes (p<5e-6) to 1799 genes (p<5e-2), AD risk genes are found consistently, and significantly (padj<1e-250) enriched among the genes changing as APPtg mice age ("APP interaction" Fig.1C ), but not in Tautg mice. The smallest set (n=92 genes with p<5e-06), also significantly enriches among the Thus, genes that enhance the risk of AD are clustering among genes that are deregulated over time with increasing Aβ-but not TAU-pathology.
Changes in gene expression exacerbate with aging in APPtg but not in TAUtg mice
To assess the functional substrate of the AD risk gene enrichment in APPTg mice, we compared the transcriptional deregulation in the two mouse models in more detail (see Fig.2A -C and Supplementary Fig S3+4) . GSEA with the GWAS gene set generated from
Marioni et al.
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, at different cut-offs for statistical significance as explained above ( and S4). However, when taking gene sets defined by increasing statistical significance (p<0.001 or smaller), the only module that persistently demonstrates significant enrichment with GWAS genes is the APPtg-Blue module (see Fig.3A ). The APPtg-Blue module is large (n=4236), and contains 62% of all the genes significantly differentially expressed in aging APPtg mice (age*genotype, which is more than expected by chance (log2 odds ratio (LOR): 2.90, p=1.54e-158)). We assume that this module provides the integrated and coordinated response of the brain to amyloid pathology. It is important to stress that despite the module being large, still significantly more AD GWAS genes are in the APPTg-Blue module than expected by chance alone (1e-250<padj<0.01). Thus, it appears that genes associated with increasing risk of AD, generally cluster within this module.
Remarkable, most of the differentially expressed genes in this module are upregulated ( Moreover, this module is highly enriched for GO categories involving immune response, cytokine production and inflammation ( Fig.3D and Supplementary Table 2 ), but the genetic evidence for the role of these genes in AD increases. In the end, the choice of the p-value threshold is arbitrary, as even SNPs with p-values up to 0.5 contribute to the PRS and therefore contain information. 6 The important insight is, however, that identified genes are implied in AD by two independent unbiased experimental approaches here: genetically, by contributing to the risk of AD in human studies, and functionally, by being part of the APPtg-Blue-response module in a mouse model for AD. 2, 6 We focus here on GWAS genes that: 1) have been associated to AD with p<0.001 as these genes are more likely to make an individual impact on disease, 2) that are present in the APPtg-Blue module, and 3) that are, additionally, significantly differentially expressed in the age*genotype comparison of APPtg mice (see Fig.3E ). The latter criterion is restrictive because we require that the gene is not only part of the APPtg-Blue response module but is also significantly altered in expression, thus part of the core response that defines the module. These three criteria show a highly significant intersection of 18 genes which is markedly better than expected by chance alone (expected 2.2 genes, padj=9.0e-11, demonstrated that observing an intersection of 18 genes among these three gene sets is highly significantly better than expected by chance ((padj = 9.0e-11, see Supplementary Table 7 and Fig.3E ). Table 6 ). All of the 18 AD risk genes are predicted SPI1 targets according to i-cisTarget (see Fig.4C Fig.4A ). 19 Thus, these top 18 GWAS genes contribute to the cellular response of microglia when facing increasing Aβ levels. The possible role of these genes together with other microglia-related previously established GWAS genes is schematically summarized in Fig.5 , and further discussed below.
Discussion
This study identifies a gene transcription module (APPtg-Blue) that is specifically induced by overexpression of mutated APP/PSEN1 (but not by MAPT) and is enriched for a large set of genes that were previously linked with SNPs associated to AD risk without reaching genome-wide significance.
Our experiments suggest that these genes are part of a pathway that characterizes the microglia response to Aβ (see Fig.5 ). While the individual effects of various SNPs on expression of these genes are likely small and biological insignificant, the combination of hundreds of such subtle alterations, if synergic in one pathway, might veer the cellular response to Aβ in a disease causing direction through biological epistasis. 20 Functionally, this co-regulatory network (the APPtg-Blue module), represents a large neuroinflammatory response involving astroglia and, overwhelmingly, microglia. These observations considerably expand previous work, strengthening the hypothesis that the major response in brain to Aβ pathology is neuroinflammation. 21, 22 Our and other data suggest that an early and profound neuroinflammatory response is an integral and perhaps even driving component in AD pathogenesis, and that Aβ is sufficient to induce this innate immune reaction. 13, 22 Our data strengthen this concept considerably by demonstrating that a large part of the GWAS-based genetic risk affects genes that are expressed in the molecular pathway defining this neuroinflammatory response to Aβ pathology.
Earlier studies have relied heavily on functional analysis and module connectivity for putative gene selection involved in AD pathogenesis, but whether these genes were also differentially expressed was not considered. 12 12 We used two independent functional criteria: genes must have a genetic association with AD at p<0.001 and show a statistically significant change in expression when exposed to increasing levels of Aβ over time, indicating that these genes are part of the cellular response. Therefore, we can predict with high confidence (BY-padj=9.0e-11) that they are indeed involved in an AD relevant disease pathway responding to Aβ pathology. It must be noted that the GWAS genes currently used were based on genomic proximity to AD-associated SNPs, which may result in spurious associations. Although this potential caveat may affect our outcome, it is unlikely that the expression of such an erroneously identified gene would be significantly altered in AD-relevant pathways and thus will not appear in our final list.
Among the prioritized SNPs, many are linked to known myeloid-expressed genes involved in innate immune pathways (see Fig.5 ). Briefly, FCER1G encodes for the gamma subunit of IgE-specific Fc receptors and plays a role in phagocytosis and microglial activation. 23 SYK is recruited by FCER1G and TYROBP (DAP-12) upon activation of TREM2, whereas LYN is localized at the plasma membrane and mediates TREM2/SYK phosphorylation. 24, 25 BLNK is a target of SYK and mediates the recruitment of
PLCG2.
25 TREML2, unlike TREM2, is reported to activate microglia and promote release of proinflammatory cytokines. 26 PYCD1 (Pycard in mouse) encodes for apoptosis-associated speck-like protein containing C-terminal caspase recruitment domain (ASC), a core component of the inflammasome complex, and has been recently linked to seeding and spreading of Aβ in mouse models of AD. 27 The lysosomal protein HEXB and glucose transporter SLC2A5 are part of the microgliome profile. 28 GRN can adopt multiple subcellular localizations from lysosomes (as granulin) to the 13 extracellular space (as progranulin) and exerts a negative control upon microglial activation in mouse models (see Fig.5 ). 29 Interestingly, all of the prioritized AD risk genes are Spi1 targets, substantiating the pivotal role of this transcription factor in the observed Aβ-induced transcriptional response. 14, 30 It remains to be clarified where, when and how in this pathway TAU pathology starts and how it contributes to disease progression towards dementia, and whether Aβ directly, or indirectly by the broad and complex neuroinflammatory (APPtg-Blue) response, induces abnormal TAU phosphorylation or conformation. Our hypothesis implies, however, that TAU pathology comes downstream of the microglia/neuroinflammatory response on Aβ because GWAS-defined genetic risk for AD is not associated with TAU-induced gene expression changes. The TAUtg transcriptional analysis does suggests that TAU induces very early down-regulation of neuronal genes ( Supplementary Fig.S2 ), which vibes with the observations that dementia correlates much better with the appearance of tangles than amyloid plaques. Besides its role in regulating immune response, the newly prioritized risk gene Syk is a known tau kinase, providing an interesting genetic link between Aβ and TAU pathology. 31 In conclusion, we hypothesize that the transition from a rather asymptomatic biochemical or prodromal phase, to the clinical, symptomatic, phase in AD, is largely determined by the combined inheritance of low-penetrant SNPs, which, as our work suggests, might affect the gene expression in the APPtg-Blue module. The concept of PRS forces us to abandon the classical gene-based view on disease etiology and to consider GWAS genes as part of a functional network. 32 Given the robustness of biological systems and (the theory of) genetic buffering, a single SNP within the network will not lead to disease. 33 However, multiple SNPs within the same network may tip the balance to a diseasecausing disturbance. Such hypothesis also provides an explanation for the conundrum that some patients with high Aβ burden succumb without clinical symptoms. 34 While Aβ might be the trigger of the disease, it is the genetic make-up of the microglia (and possibly other cell types) which determines whether a pathological response is induced. Identifying which SNPs are crucial to such network disturbances and how those SNPs lead to altered gene expression will be the next big challenge.
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Materials & Methods
Study design
The goal of the current study was to assess the enrichment of AD GWAS genes among the transcriptional responses as APPstg and TAUtg mice develop pathology over time. Given the mice' age and genotype, mice could not be distributed randomly across the experimental groups, but randomization was performed during RNA extraction and library preparation to avoid batch effects.
Library preparation was performed in a blinded fashion. Details regarding sample size, biological replicates and outliers can be found below.
Mice
The 
RNA extraction, library construction, sequencing and mapping
The left hippocampus of each mouse was homogenized in TRIzol (Invitrogen, Carlsbad, CA, USA) using 1ml syringes and 22G/26G needles and purified on mirVana spin columns according to the ).
Data pre-processing and differential expression analysis
We found in 2 of the 12 APPtg-10M mice a 46% lower expression levels of hsa-APPswe, a 26% lower expression of hsa-Psen1 L166p and a 24% reduction in mmu-Thy1 gene, which drives the expression of the transgenes. Principle component analysis (using log2(raw reads from Feature Counts +1) and the 'prcomp' function in R) also revealed that these 2 mice were closer to the 4M APPtg mice than the 10M APPtg mice (see Supplementary Fig.S1 ). In the absence of an explanation for this phenomenon, these two mice were excluded from all further analyses. 
Cell-specific datasets
Cell type specific genes sets for pyramidal neurons (n=701 genes), interneurons (n=364), astrocytes (n=239), microglia (n=435), oligodendrocytes (n=452), endothelial (n=352) and ependymal cells (n=483) were derived from Zeisel et al. 19 (Supplementary Table 1 ). Using these gene sets and a count matrix that was z-score normalized across samples, we calculated for each cell type (t) the average zscore (Ztg) for each experimental group (g) and compared this to the respective 4M WT group. We assesses significance using empirically derived p-values (see Supplementary Materials and Methods and Supplementary Fig.S5 ).
GWAS gene set enrichment analysis
Human GWAS genes derived from Marioni et al. 2 were converted to mouse orthologues using the Weighted gene co-expression network analysis (WGCNA)
The WGCNA package in R was used to build unsigned mRNA coexpression networks for APPtg and TAUtg mice separately using all 15824 expressed genes. 42 To generate an adjacency matrix with is the smallest threshold that satisfies the scale-free topology fit at R Functional annotations of the modules was performed using first GOrilla 44 and when no significant enrichment could be found, using DAVID (see Supplementary Tables 4 & 5. 45,46 GO categories were deemed significant if the FDR-corrected p-value (GOrilla) or Benjamini-based p-value <0.05 (DAVID).
To search for potential regulators in each module, we ran i-cisTarget 47 which predicts transcription factor motifs (position weight matrices) and experimental data tracks (e.g. ENCODE,
Roadmap Epigenomics Project) that are enriched in the input set of regions (i.e. genomic regions for each gene within the module). The default setting collected over 23588 features across all the databases available in i-cisTarget. Only regulators that were also expressed within the same WGCNA module were considered. Top regulators were selected based on the maximum normalized enrichment score for feature enrichment.
Gene set overlap assessment
Overlap between the GWAS p<0.001 gene set (n=314), all genes significantly differentially expressed within the APPtg age*genotype interaction comparison (n=798), genes within the APPtg-Blue module (n=4236) and the microglia-specific gene set (n=435) were assessed using SuperExactTest 15 (version 1.0.4), which calculates, based on combinatorial theory, the statistical probability of finding an overrepresentation of genes within the intersection of multiple sets, compared to random expectation. Pvalues were BY-adjusted (see Supplementary Table 7 ).
Data and software availability
All data has been submitted to the GEO database. The mouse mRNAseq data is under accession number GSE110741. The software tools used for this study include: Tophat2 (version 2.0.7, known cellular components, with previously described established GWAS 3, 4 in black, and the
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